Labetuzumab govitecan: Additional Phase I/II data

Interim data from 38 evaluable mCRC patients previously treated with >=1 irinotecan-containing regimen in the Phase II portion of an open-label, dose-escalation, U.S. Phase I/II trial showed that once...